Furthermore, in the NeoALTTO study treated with neoadjuvant lapatinib, trastuzumab, or their combination plus paclitaxel, obesity was associated with reduced access to pCR in HER2+ luminal BC patients, but not in HER2- cases (118). The gene discussed is ERBB2; the disease is obesity due to melanocortin 4 receptor deficiency.